GSK Gains Clarity For Pharma Focus Through Novartis Consumer JV Buy
Executive Summary
GSK removed some uncertainty about how much it could invest in pharma R&D and business development by purchasing Novartis' share of the firms' Consumer Healthcare Joint Venture. Now it can more accurately allocate capital as it prepares for battle in HIV and braces for Advair generics.
You may also be interested in...
Five Reasons Why GSK Spinning Off Consumer Is Not So Straightforward
GSK once again provided grist to the stock market rumor mill over the weekend, with reports emerging that its chairman has been talking to major shareholders about the possibility of splitting up the company. But there are reasons to doubt whether talks would lead to action any time soon.
Five Reasons Why GSK Spinning Off Consumer Health Wouldn't Be Easy
GSK once again provided grist to the stock market rumor mill recently with reports of its chairman talking to major shareholders about the possibility of splitting up the company. But there are reasons to doubt whether talks would lead to action any time soon.
Biopharma Quarterly Dealmaking Statistics, Q1 2018
Biopharma financing started the year solidly with $16.6 billion in total deal value, a 14% increase over the previous quarter. Q1 2018 biopharma merger and acquisition deal value, led by Cigna's $67 billion buy of Express Scripts, topped even the previous all-time-high set in Q4 2107, while alliances totaled $30.7 billion and featured big oncology and neurology partnerships.